0.76
+0.039(+5.41%)
Currency In USD
| Previous Close | 0.72 |
| Open | 0.73 |
| Day High | 0.76 |
| Day Low | 0.72 |
| 52-Week High | 4.89 |
| 52-Week Low | 0.6 |
| Volume | 79,067 |
| Average Volume | 309,491 |
| Market Cap | 3.64M |
| PE | -0.13 |
| EPS | -6.07 |
| Moving Average 50 Days | 0.72 |
| Moving Average 200 Days | 1.6 |
| Change | 0.04 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of July 10, 2025 at a share price of $0.76. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.21 as of July 10, 2025 at a share price of $0.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
GlobeNewswire Inc.
Yesterday at 12:45 PM GMT
Figure: 1 Palisade Bio, Inc. Appoints Emil Chuang, MB BS FRACP to its Board of Directors Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcera
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
GlobeNewswire Inc.
May 27, 2025 12:30 PM GMT
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
GlobeNewswire Inc.
May 06, 2025 12:30 PM GMT
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and